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Merkel cell carcinoma (MCC) is an aggressive neuroendocrine skin cancer that is three times more 
likely to be lethal than a malignant melanoma. At least 75% of MCC tumors are associated with an 
oncogenic virus, Merkel cell polyomavirus (MCV). The incidence of MCC has tripled in the last 20 
years. Furthermore, there is a 5-fold to 50-fold increase in incidence of this cancer in patients with 
chronic immune suppression, including HIV/AIDS, hematologic malignancies, autoimmune disease 
or solid organ transplantation. Since the majority of MCC tumors are associated with a virus, 
immunosuppression is hypothesized to worsen MCC-specific prognosis in addition to increasing risk 
for developing MCC. To determine if immunocompromised patients have worsened prognoses, 
researchers in the laboratory of Dr. Paul Nghiem of the Clinical Research Division and the Division 
of Dermatology at the University of Washington examined MCC-specific survival in a cohort of 
immune competent and suppressed patients. 
MCC prognosis depends on the stage of disease presentation: 5-year relative survival decreases 
from 64% to 39% to 18% for local, nodal, and metastatic disease, respectively. Even with successful 
treatment, nearly 50% of MCC patients relapse. Led by co-authors Drs. Jayasri Iyer and Kelly 
Paulson, the current study examined 471 MCC patients, 41 of whom had systemic immune 
suppression and 430 of whom were not immune suppressed. Three-year overall survival was 
decreased in MCC patients with immune suppression to 33%, compared to patients without immune 
suppression at 59% (hazard ratio 2.1; P < 0.01). The small number of patients in this study 
prevented the researchers from determining the individual contributions of different forms of immune 
suppression to MCC outcomes. 
To account for differences in death rates from causes other than MCC, the researchers also used 
competing risk regression analysis, where MCC-related deaths were considered events and non-
related deaths were considered competing events. Using this analysis, immune suppression was a 
significant predictor of decreased MCC-specific survival (hazard ratio 3.0; 95% confidence interval 
1.8-4.8; P < 0.01), with immunosuppressed patients having a three-year overall survival at half that 
of the comparison group (40% vs. 74%; P < 0.05). Multivariate competing risk regression analysis 
further confirmed that immunosuppression was an independent predictor of MCC-specific survival 
independent of cancer stage, age, or gender (hazard ratio 3.8; P < 0.01). 
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Previously, the Nghiem Laboratory investigated how the immune system controls MCC progression. 
MCV-specific antibodies increase with increased tumor burden in MCC patients but do not protect 
from disease progression, while the presence of infiltrating lymphocytes in MCC tumors is 
associated with markedly improved patient outcomes (Paulson et al., 2010, Paulson et al., 2011, 
Bhatia et al., 2011). Similar to other tumor viruses, most people infected with MCV do not develop 
MCC, emphasizing the importance of other co-factors involved in MCC development, including 
increased age, sun exposure, and immune dysregulation. These studies and others help explain 
why the incidence of MCC is increased in immunosuppressed patients, and why 
immunosuppression can lead to poorer MCC-specific outcomes. Harnessing the ability of the 
immune system to target MCV and control MCC development may lead to future treatments for MCC 
patients. 
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Images courtesy of Kelly Paulson and Paul 
Nghiem. 
A) Image of Merkel cell carcinoma on the skin of 
a patient. B) Immune suppressed individuals 
(n=41) had significantly decreased MCC-specific 
survival as compared to patients without 
immune suppression (n=430) on univariate 
(hazard ratio 3.0; P <0.01) and multivariate 
(hazard ratio 3.8; P <0.01) competing risk 
regression analysis. 
 
